Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors
Latest Information Update: 20 Feb 2025
At a glance
- Drugs RiMO-301 (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Coordination Pharmaceuticals; RiMO Therapeutics
Most Recent Events
- 13 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 13 Feb 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 06 Jun 2023 Results (n=25) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.